DEBORAH VALIN: Open Payments
NPI 1043365802 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$289 in 13 payments from 7 companies in 2025. Trend: 2023 $76 · 2024 $408 · 2025 $289
Food & beverage: $289
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 3 | $80 |
| GlaxoSmithKline, LLC. | 3 | $54 |
| Novo Nordisk Inc | 2 | $47 |
| Lilly USA, LLC | 2 | $38 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Currax Pharmaceuticals LLC | 1 | $17 |
Products named: ORENCIA, BENLYSTA, Wegovy, MOUNJARO, UNITHROID, OPSUMIT, CONTRAVE.
Industry payments across CT — which companies pay providers there.
